



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Brentuximab vedotin

Cat. No.:	HY-P99107
CAS No.:	914088-09-8
Target:	Apoptosis; Antibody-Drug Conjugates (ADCs); TNF Receptor
Pathway:	Apoptosis; Antibody-drug Conjugate/ADC Related
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

## Brentuximab vedotin

### BIOLOGICAL ACTIVITY

<b>Description</b>	Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE). Brentuximab vedotin inhibits CD30-positive cells with an IC <sub>50</sub> of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma <sup>[1][2]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 2.5 ng/mL (CD30) <sup>[2]</sup>																
<b>In Vitro</b>	<p>Brentuximab vedotin (cAC10-vcMMAE) (1 µg/mL; 96 h) shows cytotoxicity to CD30<sup>+</sup> in Karpas 299 cells<sup>[2]</sup>.</p> <p>?Brentuximab vedotin (CAC10-VCMMMAE) (1 µg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell ?death<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Karpas 299 cells</td> </tr> <tr> <td>Concentration:</td> <td>1 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>96 h</td> </tr> <tr> <td>Result:</td> <td>Showed cytotoxicity to CD30<sup>+</sup> Karpas 299 cells with an IC<sub>50</sub> value of 2.5 ng/mL.</td> </tr> </table> <p>Cell Cycle Analysis<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>L540 cells</td> </tr> <tr> <td>Concentration:</td> <td>1 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>12, 24, and 48 h</td> </tr> <tr> <td>Result:</td> <td>Selectively induced growth arrest in G2/M phase to apoptotic cell death.</td> </tr> </table>	Cell Line:	Karpas 299 cells	Concentration:	1 µg/mL	Incubation Time:	96 h	Result:	Showed cytotoxicity to CD30 <sup>+</sup> Karpas 299 cells with an IC <sub>50</sub> value of 2.5 ng/mL.	Cell Line:	L540 cells	Concentration:	1 µg/mL	Incubation Time:	12, 24, and 48 h	Result:	Selectively induced growth arrest in G2/M phase to apoptotic cell death.
Cell Line:	Karpas 299 cells																
Concentration:	1 µg/mL																
Incubation Time:	96 h																
Result:	Showed cytotoxicity to CD30 <sup>+</sup> Karpas 299 cells with an IC <sub>50</sub> value of 2.5 ng/mL.																
Cell Line:	L540 cells																
Concentration:	1 µg/mL																
Incubation Time:	12, 24, and 48 h																
Result:	Selectively induced growth arrest in G2/M phase to apoptotic cell death.																
<b>In Vivo</b>	<p>Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg<sup>[2]</sup>.</p> <p>?Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression<sup>[2]</sup>.</p>																

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice <sup>[2]</sup>
Dosage:	10 to 120 mg/kg
Administration:	Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:	Showed an maximum tolerated dose between 30 and 40 mg/kg.
Animal Model:	SCID mice <sup>[2]</sup>
Dosage:	0.3 and 1 mg/kg
Administration:	Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:	Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.

## REFERENCES

[1]. Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. *Curr Hematol Malig Rep.* 2020 Feb;15(1):9-19.

[2]. Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. *Blood.* 2003 Aug 15;102(4):1458-65.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA